… ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology LEIDEN, the Netherlands, Jan. 08, … fibrosis targets,” said Daniel A. de Boer, CEO of ProQR. “We look forward to working closely with the team at …
… ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Agreement … FERRAND, France, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company …
… ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day LEIDEN, … in non-core therapeutic areas and non-rare diseases. “The ‘ProQR Vision 2023’ strategy presents a clear path for ProQR …
… European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10 Access … vision with sepofarsen,” stated Daniel A. de Boer, CEO of ProQR. “Looking ahead, our goal is for sepofarsen to reach …
… ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives … Orphan Drug Designation from FDA and EMA Key Updates ProQR’s drug candidate QRX-421 for Usher syndrome receives …
… ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives … Orphan Drug Designation from FDA and EMA Key Updates ProQR’s QRX-411 receives Orphan Drug Designation by the FDA …
… ProQR’s Drug Candidate QR-110 for Leber’s Congenital … LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that … mutation,” said Daniel de Boer, Chief Executive Officer of ProQR. “Obtaining orphan drug designations from EMA and FDA …
… will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A … people with USH2A mutations. The study — known as RUSH2A (“R” stands for “rate of progression”) — was launched in 2017 …